Recently added

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial

PERNAS SIMON, SONIA; Pascual, Tomás; Villacampa Javierre, Guillermo; Oliveira, Mafalda; Escriva de Romani, Santiago; Paré, Laia; Nuciforo, Paolo (Elsevier, 2025-09)

IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

Powderly, John; Imbimbo, Martina; MARTIN ROMANO, PATRICIA; McKean, Meredith; ITALIANO, ANTOINE; Macarulla, Teresa (American Association for Cancer Research, 2025-09)

Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches

Fariña Morillas, Maria; Ollé i Monràs, Laia; de Rojas de Pablo, Isabel; Seoane Fernández, Jose Antonio; Maas, Silvana; Segura, Miguel F. (Taylor & Francis, 2025)

Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study

Niger, Monica; Melzer, Anna; Terán Brage, Eduardo; rimini, margherita; Castet, Florian; Rizzato, Mario Domenico; Pressiani, Tiziana; Vega, kreina; Macarulla, Teresa (Wiley, 2025-09)

Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer

Karta, Jessica; Meyers, Marianne; Rodriguez, Fabien; Koncina, Eric; Gilson, Cédric; Klein, Eliane; Alonso Landeira, Lidia; Aguilera Pujabet, Mònica; Nuciforo, Paolo (EMBO Press, 2025-10)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial

IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches

Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study

Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial ﻿

IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors ﻿

Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches ﻿

Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study ﻿

Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer ﻿

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial

IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches

Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study

Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer